# US 2016/0354430 A1 · Hexadepsipeptide analogues as anticancer compounds

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2016/0354430 A1
- Document ID: US20160354430A1
- Status: Published application
- Kind: A1
- Application number: 15/240,509
- Filed: 2016-08-18
- Published: 2016-12-08
- Earliest claimed: 2012-05-07
- Assignees: Piramal Enterprises Limited
- Applicants: Piramal Enterprises Limited
- Inventors: Prabhu Dutt Mishra; Sreekumar Sankaranarayanan Eyyammadichiyl; Saji David GEORGE; Shailendra SONAWANE; Narayan Subhash CHAKOR; Abhijit ROYCHOWDHURY; Rajiv SHARMA
- Web page: https://patentgrep.com/patent/US20160354430A1

## CPC

- A61K 38/15: Depsipeptides; Derivatives thereof
- A61P 35/00: Antineoplastic agents
- A61P 35/02: specific for leukemia
- C07K 7/64: Cyclic peptides containing only normal peptide links
- C07K 11/02: cyclic, e.g. valinomycins {; Derivatives thereof}
- A61K 38/00: Medicinal preparations containing peptides (peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)

## Abstract

This invention relates to a method of treatment of cancer comprising administering compound of Formula (1) or derivatives or pharmaceutically acceptable salts thereof.

## Claims

### Claim 1

A method for the treatment of cancer, comprising administering to a subject in need thereof, a therapeutically effective amount of the compound of Formula (1);
wherein in the compound of Formula (1), when the bond represents a single bond and R1 is H; the said compound is referred to as the compound of Formula (1a); and when the bond is a double bond and R1 is absent; the said compound is referred to as the compound of Formula (1b);
or an isomer or a tautomer or a pharmaceutically acceptable salt thereof.

### Claim 2 (depends on 1)

The method according to claim 1, wherein Formula (1) is the compound of Formula (1a);
characterized by:
a) molecular weight of 826.9,
b) molecular formula C37H62N8O13.
c) IR (KBr) spectrum 3325, 2960, 2872, 1755, 1641, 1524, 1445, 1331, 1306, 1288 and 1254 cm−1,
d) 1H NMR spectrum (500 MHz, CDCl3): δ 9.20, 8.00, 7.10, 6.90, 6.40, 6.10, 5.40, 5.38, 5.29, 5.10, 4.90, 4.80, 4.70, 4.60, 3.90, 3.70, 3.15, 2.70, 2.30, 2.10, 1.98, 1.95, 1.77, 1.71, 1.68, 1.60, 1.52, 1.40, 1.15, 1.10, 1.05, 0.98, 0.95, 0.90, 0.88 and 0.85, and
e) 13C NMR spectrum (75 MHz, CDCl3): δ 176.0, 172.0 (3), 171.0, 170.0, 169.0, 99.9, 78.9, 77.2, 71.7, 53.5, 52.9, 49.3, 49.0, 47.1, 46.7, 46.2, 42.2, 41.0, 39.8, 29.9, 27.4, 24.8, 24.6, 24.2, 24.1, 23.2, 21.7, 21.5 (2), 20.6, 19.9, 19.4, 18.1, 12.9 and 11.7.

### Claim 3 (depends on 1)

The method according to claim 1, wherein Formula (1) is the compound of Formula (1b);
characterized by:
a) molecular weight of 824.4,
b) molecular formula C37H60N8O13,
c) IR (KBr): 3342, 3030, 2953, 1752, 1650, 1524, 1421, 1293, 1255 and 1239 cm−1,
d) 1H NMR spectrum (500 MHz, CDCl3): δ 9.20, 8.00, 7.19, 7.0, 6.18, 6.14, 5.80, 5.41, 5.39, 5.30, 5.10, 4.80 (2), 4.20, 3.70, 3.19, 2.62, 2.27, 2.10, 2.01, 1.98, 1.77, 1.71, 1.62, 1.58, 1.44, 1.40, 1.39, 1.37, 1.20, 1.10, 1.05, 0.96, 0.91, 0.90, 0.86, and 0.85, and
e) 13C NMR spectrum (75 MHz, CDCl3): δ 176.0, 171.8, 171.7, 170.8, 170.6, 170.3, 168.9, 144.6, 98.8, 79.0, 77.2, 71.7, 53.6, 53.5, 50.6, 49.1, 47.1, 46.4, 42.6, 41.0, 39.8, 29.9, 27.4, 24.7, 24.6, 24.2, 24.0, 22.1, 21.5, 21.4, 19.8, 19.5, 19.4, 18.1, 17.2, 12.9 and 11.8.

### Claim 4 (depends on 1)

The method according to claim 1, wherein a derivative of the compound of Formula (1) represented by the Formula (1c);
wherein,
R1 and R4 independently represent H or are absent;
R2 and R3 are independently selected from the group consisting of H, hydroxy, —O(C1-C6)alkyl and —OC(O)(C1-C6)alkyl,
represents a single bond or a double bond;
wherein,
(C1-C6)alkyl is unsubstituted or substituted with one or more groups independently selected from the group consisting of halogen, hydroxy, —O(C1-C6)alkyl, nitro, cyano, —COOH, —NH2, —NH(C1-C6)alkyl, —N[(C1-C6)alkyl]2, —NHC(O)O(C1-C6)alkyl, —NHC(O)O(C1-C6)alkyl(C6-C10)aryl, —NH-PEG and (C6-C10)aryl;
(C6-C10)aryl is unsubstituted or substituted with one or more groups independently selected from the group consisting of halogen, halo(C1-C6)alkyl, hydroxy, cyano, nitro, (C1-C6)alkyl, —O(C1-C6)alkyl, —COOH and —NH2;
and PEG is polyethylene glycol selected from the group consisting of O,O′-bis[2-(N-succinimidyl-succinylamino)ethyl]polyethylene glycol (α,ω-bis-NHS-PEG), methyl-PEG-NHS ester (MS(PEG)n where n is 24), and a branched trimethyl or succinimide ester derivative of polyethylene glycol (TMS(PEG)n, wherein n is 12);
with a proviso that if both R2 and R3 are hydroxy, then R1 and R4 are absent and represents a double bond;
or an isomer or a tautomer or a mixture thereof; or a pharmaceutically acceptable salt thereof.

### Claim 5 (depends on 4)

The method according to claim 4,
wherein: R1 and R4 are H;
R2 is —O(C1-C6)alkyl or —OC(O)(C1-C6)alkyl;
R3 is hydroxy or —O(C1-C6)alkyl;
wherein, (C1-C6)alkyl is unsubstituted or substituted with one or more groups independently selected from the group consisting of —NH2, —NHC(O)O(C1-C6)alkyl(C6-C10)aryl and —NH-PEG;
or an isomer or a tautomer or a mixture thereof; or a pharmaceutically acceptable salt thereof.

### Claim 6 (depends on 4)

The method according to claim 4,
wherein:
R1 and R4 independently represent H or are absent;
R2 and R3 are independently selected from H and hydroxy;
represents a single bond or a double bond;
with a proviso that if both R2 and R3 are hydroxy, then R1 and R4 are absent and represents a double bond;
or an isomer or a tautomer or a mixture thereof; or a pharmaceutically acceptable salt thereof.

### Claim 7 (depends on 4)

The method according to claim 4, wherein the compound is:
or an isomer or a tautomer or a mixture thereof; or a pharmaceutically acceptable salt thereof.

### Claim 8 (depends on 1)

The method according to claim 1, wherein the cancer is leukemia, lung cancer, brain tumors, non-Hodgkin's lymphoma, Hodgkin's disease, liver cancer, kidney cancer, bladder cancer, cancer of urinary tract, breast cancer, head and neck cancer, endometrial cancer, lymphoma, melanoma, cervical cancer, thyroid cancer, gastric cancer, germ cell tumor, cholangiocarcinoma, extracranial cancer, sarcoma, mesothelioma, malignant fibrous histiocytoma of bone, retinoblastoma, esophageal cancer, multiple myeloma, pancreatic cancer, ependymoma, neuroblastoma, skin cancer, ovarian cancer, recurrent ovarian cancer, prostate cancer, testicular, cancer, colorectal cancer, lymphoproliferative disease, refractory multiple myeloma, resistant multiple myeloma or myeloproliferative disorder.

### Claim 9 (depends on 1)

The method according to claim 1, wherein the cancer is acute lymphocytic leukemia, acute myeloid leukemia, adult acute myeloid leukemia, acute lymphoblastic leukemia, chronic lymphocytic leukemia, chronic myeloid leukemia, hairy cell leukemia, non-small-cell lung cancer, small-cell lung cancer, brain stem glioma, glioblastoma, astrocytoma including cerebellar astrocytoma and cerebral astrocytoma, visual pathway glioma, pineal tumors, medulloblastoma, primary central nervous system lymphoma, mantle cell lymphoma, Hodgkin's disease, hepatocellular carcinoma, renal cell carcinoma, bladder cancer, cancer of urinary tract, osteosarcoma, breast cancer, endometrial cancer oral cancer, melanoma, cervical cancer, thyroid cancer, gastric cancer, malignant fibrous histiocytoma of bone, retinoblastoma, esophageal cancer, multiple myeloma, pancreatic cancer, neuroblastoma, skin cancer, ovarian cancer, prostate cancer, testicular cancer, colorectal cancer, lymphoproliferative disease or myeloproliferative disorder.

### Claim 10 (depends on 9)

The method according to claim 9, wherein the cancer is acute lymphocytic leukemia, acute myeloid leukemia, adult acute myeloid leukemia, acute lymphoblastic leukemia, chronic lymphocytic leukemia, chronic myeloid leukemia, hairy cell leukemia, non-small-cell lung cancer, small-cell lung cancer, brain stem glioma, glioblastoma, astrocytoma including cerebellar astrocytoma and cerebral astrocytoma, medulloblastoma, renal cell carcinoma, bladder cancer, cancer of urinary tract, breast cancer, oral cancer, melanoma, cervical cancer, thyroid cancer, gastric cancer, pancreatic cancer, prostate cancer or colorectal cancer.
